Table 1.
IC50 values (µM) relative to AziRu and to the effective ruthenium concentration inserted in the Ru(III)-incorporating POPC- and DOTAP-based liposomes in the indicated cell lines following 48 or 72 h of incubation in vitro. IC50 values are reported as mean ± SEM.
| IC50 (μM) | ||||||
|---|---|---|---|---|---|---|
| MCF-7 | WiDr | C6 | HeLa | L6 | HaCaT | |
| NAMI-A [78] | 620 ± 30 | - | - | 626 ± 45 | - | - |
| AziRu [77,79] | 305 ± 16 [77] | 441 ± 20 [77] | 318 ± 12 [77] | 382 ± 19 [79] | > 500 [79] | > 500 [79] |
| POPC-based formulations | ||||||
| ToThyRu/POPC [77,134] | 27.8 ± 0.1 [134] | 75 ± 4 [77] | 36 ± 8 [77] | - | - | - |
| HoThyRu/POPC [77] | 7 ± 4 | 40 ± 5 | 81 ± 7 | - | - | - |
| DoHuRu/POPC [77,134] | 18.9 ± 0.1 [134] | 99 ± 5 [77] | 24 ± 5 [77] | - | - | - |
| ToThyCholRu/POPC [79,105] | 70 ± 12 [105] | 165 ± 10 [105] | - | - | >500 [79] | >500 [79] |
| HoUrRu/POPC [107] | 14 ± 7 | 20 ± 8 | - | - | - | - |
| DOTAP-based formulations | ||||||
| ToThyRu/DOTAP [106,134] | 10.1 ± 0.1 [134] | 50 ± 11 [106] | 54 ± 8 [106] | - | - | - |
| HoThyRu/DOTAP [100,106] | 13 ± 4 [100] | 65 ± 8 [106] | 43 ± 11 [106] | - | - | - |
| DoHuRu/DOTAP [106,134] | 10.3 ± 0.2 [134] | 41 ± 10 [106] | 34 ± 9 [106] | - | - | - |
| ToThyCholRu/DOTAP [79] | 13 ± 2 | 23 ± 8 | - | 34 ± 4 | 187 ± 1 | 377 ± 3 |
| HoUrRu/DOTAP [107] | 8 ± 5 | 12 ± 5 | - | - | - | - |
| I/DOTAP [110] | 31.2 ± 2.7 | - | 35.4 ± 2.7 | 45.6 ± 3 | - | >150 |